An economic model of long-term use of celecoxib in patients with osteoarthritis

por Loyd, Michael, Rublee, Dale, Jacobs, Philip
Publicado 2007

The association of comorbidities, utilization and costs for patients identified with low back pain

por Ritzwoller, Debra P, Crounse, Laurie, Shetterly, Susan, Rublee, Dale
Publicado 2006

Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]

por Rublee, Dale, Opal, Steven M, Schramm, Wolfgang, Keinecke, Heinz-Otto, Knaub, Sigurd
Publicado 2002

Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences

por Lanitis, Tereza, Leipold, Robert, Hamilton, Melissa, Rublee, Dale, Quon, Peter, Browne, Chantelle, Cohen, Alexander T.
Publicado en BMC Health Serv Res (2017)

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation

por Dorian, Paul, Kongnakorn, Thitima, Phatak, Hemant, Rublee, Dale A., Kuznik, Andreas, Lanitis, Tereza, Liu, Larry Z., Iloeje, Uchenna, Hernandez, Luis, Lip, Gregory Y.H.
Publicado 2014

Reverse Engineering and Evaluation of Prediction Models for Progression to Type 2 Diabetes: An Application of Machine Learning Using Electronic Health Records

por Anderson, Jeffrey P., Parikh, Jignesh R., Shenfeld, Daniel K., Ivanov, Vladimir, Marks, Casey, Church, Bruce W., Laramie, Jason M., Mardekian, Jack, Piper, Beth Anne, Willke, Richard J., Rublee, Dale A.
Publicado en J Diabetes Sci Technol (2015)